Haemophilia A News and Research

RSS
Hemophilia A is an X-linked, recessive, bleeding disorder caused by a deficiency in the activity of coagulation factor VIII. Affected individuals develop a variable phenotype of hemorrhage into joints and muscles, easy bruising, and prolonged bleeding from wounds. The disorder is caused by heterogeneous mutations in the factor VIII gene which maps to Xq28.
Elite Team GB cyclist launches 'Little Bleeders' to tackle inactivity in young haemophilia patients

Elite Team GB cyclist launches 'Little Bleeders' to tackle inactivity in young haemophilia patients

New European study emphasizes need to enhance standard of haemophilia care in real life

New European study emphasizes need to enhance standard of haemophilia care in real life

Specialty pharmaceuticals: an interview with David Moran, Clinigen SP

Specialty pharmaceuticals: an interview with David Moran, Clinigen SP

Coagadex now available for rare bleeding disorder patients in the UK

Coagadex now available for rare bleeding disorder patients in the UK

European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

New €5.6 million project aims to develop cell-based haemophilia A therapy

New €5.6 million project aims to develop cell-based haemophilia A therapy

Improved gene therapy treatment shows promise in mice with cystic fibrosis

Improved gene therapy treatment shows promise in mice with cystic fibrosis

Simple, low risk blood test can detect foetal blood group and genetic conditions in unborn babies

Simple, low risk blood test can detect foetal blood group and genetic conditions in unborn babies

Approval to start trial of Videregen's replacement trachea technology

Approval to start trial of Videregen's replacement trachea technology

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

New report on different treatment strategies for haemophilia published

New report on different treatment strategies for haemophilia published

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Global haemophilia therapeutics market estimated to reach $13.43 billion in 2019

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Added benefit of simoctocog alfa not proven for haemophilia A

Added benefit of simoctocog alfa not proven for haemophilia A

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Novo Nordisk reports positive data from Novoeight phase 3 study in people with haemophilia A

Researchers set up innovative project to monitor physical activity of patients with haemophilia

Researchers set up innovative project to monitor physical activity of patients with haemophilia

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

EMA recommends marketing authorisation for Octapharma’s human cell line recombinant human FVIII, Nuwiq

Study: Added benefit of turoctocog alfa is not proven

Study: Added benefit of turoctocog alfa is not proven